Merck and Pfizer announce new Fast Track designation for Merkel cell treatment
Merck KGaA, Darmstadt, Germany and Pfizer on Wednesday announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to avelumab, a treatment for metastatic Merkel cell carcinoma. Read More »